Herpes simplex vaccine - Agenus

Drug Profile

Herpes simplex vaccine - Agenus

Alternative Names: AG-707; HerpV; rhHSP70-PC

Latest Information Update: 26 Oct 2015

Price : $50

At a glance

  • Originator Antigenics
  • Developer Agenus
  • Class Viral vaccines
  • Mechanism of Action CD4-positive T lymphocyte stimulants; CD8 positive T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Herpes simplex virus infections

Highest Development Phases

  • Suspended Herpes simplex virus type 2 infections

Most Recent Events

  • 16 Mar 2015 Agenus has patent protection for HerpV vaccine in USA
  • 01 Jan 2015 Agenus completes a phase II trial in Herpes simplex virus infections (recurrent, adjunctive therapy) in USA (NCT01687595)
  • 26 Jun 2014 HerpV is available for licensing (\http://www.agenusbio.com/\)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top